

Helen Toledano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3102511/publications.pdf>

Version: 2024-02-01

37
papers

1,867
citations

840776

11
h-index

477307

29
g-index

40
all docs

40
docs citations

40
times ranked

4442
citing authors

#	ARTICLE	IF	CITATIONS
1	Optic pathway glioma and endocrine disorders in patients with and without NF1. <i>Pediatric Research</i> , 2023, 93, 233-241.	2.3	4
2	Postoperative hydrocephalus management may cause delays in adjuvant treatment following paediatric posterior fossa tumour resection: a multicentre retrospective observational study. <i>Child's Nervous System</i> , 2022, 38, 311-317.	1.1	6
3	COVID-19 infection in pediatric patients treated for cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 448-454.	2.2	3
4	Diagenic inheritance of germline <i>POLE</i> and <i>PMS2</i> pathogenic variants causes a unique condition associated with pediatric cancer predisposition. <i>Clinical Genetics</i> , 2022, 101, 442-447.	2.0	5
5	Hyperlactatemia in children following brain tumor resection: prevalence, associated factors, and clinical significance. <i>Child's Nervous System</i> , 2022, 38, 739-745.	1.1	0
6	Genetic Alteration Analysis of IDH1, IDH2, CDKN2A, MYB and MYBL1 in Pediatric Low-Grade Gliomas. <i>Frontiers in Surgery</i> , 2022, 9, 880048.	1.4	2
7	HGG-22. Uptake of investigational therapy in children with High Grade Glioma. <i>Neuro-Oncology</i> , 2022, 24, i65-i65.	1.2	0
8	OTHR-37. Pediatrics Cutaneous Reactions in Patient Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib. <i>Neuro-Oncology</i> , 2022, 24, i155-i155.	1.2	1
9	Differences in RNA and microRNA Expression Between PTCH1- and SUFU-mutated Medulloblastoma. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 335-347.	2.0	4
10	OMIC-08. COMPOUND HETEROZYGOSITY OF POLE AND PMS2 LEADS TO CMMRD-LIKE PHENOTYPE- POLYNCH-SYNDROME. <i>Neuro-Oncology</i> , 2021, 23, i38-i39.	1.2	0
11	Delayed diagnosis and treatment of children with cancer during the COVID-19 pandemic. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1569-1574.	2.2	16
12	Classifying Medulloblastoma Subgroups Based on Small, Clinically Achievable Gene Sets. <i>Frontiers in Oncology</i> , 2021, 11, 637482.	2.8	6
13	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
14	Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias. <i>British Journal of Haematology</i> , 2021, 193, 570-580.	2.5	9
15	The great mimicker: Phenotypic overlap between constitutional mismatch repair deficiency and Tuberous Sclerosis complex. <i>Clinical Genetics</i> , 2020, 97, 296-304.	2.0	5
16	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	7.7	65
17	Proptosis due to intraorbital space-occupying lesions in children. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 2541-2550.	1.9	1
18	Paediatric systemic lupus erythematosus as a manifestation of constitutional mismatch repair deficiency. <i>Journal of Medical Genetics</i> , 2020, 57, 505-508.	3.2	7

#	ARTICLE	IF	CITATIONS
19	The Need to Look for Visual Deficit After Stroke in Children. <i>Frontiers in Neurology</i> , 2020, 11, 617.	2.4	2
20	NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1. <i>Neuro-Oncology</i> , 2020, 22, iii418-iii418.	1.2	0
21	SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 859-866.	2.3	2
22	MBCL-12. METASTATIC DISEASE IN THE SUPRASSELLAR AREA AT DIAGNOSIS IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i119-i119.	1.2	0
23	Use of Optical Coherence Tomography to Detect Retinal Nerve Fiber Loss in Children With Optic Pathway Glioma. <i>Frontiers in Neurology</i> , 2018, 9, 1102.	2.4	12
24	MBRS-27. DIFFERENCES IN RNA AND MIRNA EXPRESSION BETWEEN PTCH AND SUFU MUTATED MEDULLOBLASTOMA IN TWO PATIENTS WITH GORLINâ€™S SYNDROME. <i>Neuro-Oncology</i> , 2018, 20, i134-i134.	1.2	0
25	MicroRNA–mRNA expression profiles associated with medulloblastoma subgroup 4. <i>Cancer Management and Research</i> , 2018, Volume 10, 339-352.	1.9	11
26	Sporadic desmoid tumors in the pediatric population: A single center experience and review of the literature. <i>Journal of Pediatric Surgery</i> , 2017, 52, 1637-1641.	1.6	11
27	Prognostic relevance of miRâ€124â€p and its target <i>TP53INP1</i> in pediatric ependymoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 639-650.	2.8	16
28	Preferential sites of metastatic relapse on MRI of initially localized ependymoma in children. <i>Clinical Imaging</i> , 2017, 44, 12-15.	1.5	3
29	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
30	Fluorescence Lifetime Imaging Microscopy, a Novel Diagnostic Tool for Metastatic Cell Detection in the Cerebrospinal Fluid of Children with Medulloblastoma. <i>Scientific Reports</i> , 2017, 7, 3648.	3.3	23
31	NU-06HOSPITAL BASED HOME OUTREACH PROGRAM FOR CHILDREN WITH BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016, 18, iii136.1-iii136.	1.2	0
32	Correspondence on â€œNeurocutaneous Syndromes and Brain Tumorsâ€. <i>Journal of Child Neurology</i> , 2016, 31, 944-944.	1.4	0
33	Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity. <i>Pediatric Blood and Cancer</i> , 2016, 63, 418-427.	1.5	32
34	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
35	Acquired nystagmus as the initial presenting sign of chiasmal glioma in young children. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 694-700.	1.6	16
36	Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 909-916.	2.3	10

#	ARTICLE	IF	CITATIONS
37	Homozygosity of MSH2 c.1906Gâ†'C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. <i>Familial Cancer</i> , 2009, 8, 187-194.	1.9	26